BRIEF-Quanterix To Acquire Akoya Biosciences

Reuters

Jan 10, 2025

Jan 10 (Reuters) - Akoya Biosciences Inc :

* QUANTERIX TO ACQUIRE AKOYA BIOSCIENCES, CREATING THE FIRST INTEGRATED SOLUTION FOR ULTRA-SENSITIVE DETECTION OF BLOOD- AND TISSUE-BASED PROTEIN BIOMARKERS

* QUANTERIX CORP - TO ACQUIRE AKOYA BIOSCIENCES IN ALL-STOCK TRANSACTION

* QUANTERIX CORP - AKOYA SHAREHOLDERS TO RECEIVE 0.318 SHARES OF QUANTERIX STOCK PER SHARE

* QUANTERIX CORP - EXPECTED $40 MILLION ANNUAL COST SYNERGIES BY END OF 2026

* QUANTERIX CORP - SHAREHOLDERS TO OWN 70% OF COMBINED COMPANY

Source text: Further company coverage:

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2502857142"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2502857142\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2502857142?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-10 20:29","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2502857142","market":"us","top_or_hot":-1,"title":"BRIEF-Quanterix To Acquire Akoya Biosciences","media":"Reuters","content":"<html><body><p>Jan 10 (Reuters) - Akoya Biosciences Inc   :</p><p>   * QUANTERIX TO ACQUIRE AKOYA BIOSCIENCES, CREATING THE FIRST INTEGRATED SOLUTION FOR ULTRA-SENSITIVE DETECTION OF BLOOD- AND TISSUE-BASED PROTEIN BIOMARKERS</p><p>   * QUANTERIX TO ACQUIRE AKOYA BIOSCIENCES, CREATING THE FIRST INTEGRATED SOLUTION FOR ULTRA-SENSITIVE DETECTION OF BLOOD- AND TISSUE-BASED PROTEIN BIOMARKERS</p><p>   * QUANTERIX CORP - TO ACQUIRE AKOYA BIOSCIENCES IN ALL-STOCK TRANSACTION</p><p>   * QUANTERIX CORP - AKOYA SHAREHOLDERS TO RECEIVE 0.318 SHARES OF QUANTERIX STOCK PER SHARE</p><p>   * QUANTERIX CORP - EXPECTED $40 MILLION ANNUAL COST SYNERGIES BY END OF 2026</p><p>   * QUANTERIX CORP - SHAREHOLDERS TO OWN 70% OF COMBINED COMPANY</p><p>Source text:    Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Quanterix To Acquire Akoya Biosciences</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Quanterix To Acquire Akoya Biosciences\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-01-10 20:29</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>Jan 10 (Reuters) - Akoya Biosciences Inc   :</p><p>   * QUANTERIX TO ACQUIRE AKOYA BIOSCIENCES, CREATING THE FIRST INTEGRATED SOLUTION FOR ULTRA-SENSITIVE DETECTION OF BLOOD- AND TISSUE-BASED PROTEIN BIOMARKERS</p><p>   * QUANTERIX TO ACQUIRE AKOYA BIOSCIENCES, CREATING THE FIRST INTEGRATED SOLUTION FOR ULTRA-SENSITIVE DETECTION OF BLOOD- AND TISSUE-BASED PROTEIN BIOMARKERS</p><p>   * QUANTERIX CORP - TO ACQUIRE AKOYA BIOSCIENCES IN ALL-STOCK TRANSACTION</p><p>   * QUANTERIX CORP - AKOYA SHAREHOLDERS TO RECEIVE 0.318 SHARES OF QUANTERIX STOCK PER SHARE</p><p>   * QUANTERIX CORP - EXPECTED $40 MILLION ANNUAL COST SYNERGIES BY END OF 2026</p><p>   * QUANTERIX CORP - SHAREHOLDERS TO OWN 70% OF COMBINED COMPANY</p><p>Source text:    Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4121","symbol_name":"生命科学工具和服务","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2502857142","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2502857142","pubTimestamp":1736512195,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"Jan 10  - Akoya Biosciences Inc   :   * QUANTERIX TO ACQUIRE AKOYA BIOSCIENCES, CREATING THE FIRST INTEGRATED SOLUTION FOR ULTRA-SENSITIVE DETECTION OF BLOOD- AND TISSUE-BASED PROTEIN BIOMARKERS   * QUANTERIX TO ACQUIRE AKOYA BIOSCIENCES, CREATING THE FIRST INTEGRATED SOLUTION FOR ULTRA-SENSITIVE DETECTION OF BLOOD- AND TISSUE-BASED PROTEIN BIOMARKERS   * QUANTERIX CORP - TO ACQUIRE AKOYA BIOSCIENCES IN ALL-STOCK TRANSACTION   * QUANTERIX CORP - AKOYA SHAREHOLDERS TO RECEIVE 0.318 SHARES OF QUANTERIX STOCK PER SHARE   * QUANTERIX CORP - EXPECTED $40 MILLION ANNUAL COST SYNERGIES BY END OF 2026   * QUANTERIX CORP - SHAREHOLDERS TO OWN 70% OF COMBINED COMPANYSource text:    Further company coverage:    ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4121":"生命科学工具和服务","BK4539":"次新股","AKYA":"Akoya Biosciences, Inc.","QTRX":"Quanterix Corp"},"translate_title":"简介-Quanterix将收购Akoya Biosciences","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AKYA":1,"QTRX":0.9},"content_text":"Jan 10 (Reuters) - Akoya Biosciences Inc   :   * QUANTERIX TO ACQUIRE AKOYA BIOSCIENCES, CREATING THE FIRST INTEGRATED SOLUTION FOR ULTRA-SENSITIVE DETECTION OF BLOOD- AND TISSUE-BASED PROTEIN BIOMARKERS   * QUANTERIX TO ACQUIRE AKOYA BIOSCIENCES, CREATING THE FIRST INTEGRATED SOLUTION FOR ULTRA-SENSITIVE DETECTION OF BLOOD- AND TISSUE-BASED PROTEIN BIOMARKERS   * QUANTERIX CORP - TO ACQUIRE AKOYA BIOSCIENCES IN ALL-STOCK TRANSACTION   * QUANTERIX CORP - AKOYA SHAREHOLDERS TO RECEIVE 0.318 SHARES OF QUANTERIX STOCK PER SHARE   * QUANTERIX CORP - EXPECTED $40 MILLION ANNUAL COST SYNERGIES BY END OF 2026   * QUANTERIX CORP - SHAREHOLDERS TO OWN 70% OF COMBINED COMPANYSource text:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation,merge","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}